Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LY5625573 in Healthy Participants and Those With Elevated C-Reactive Protein
NCT07867340Phase 1Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Primary completion
- Jan 2027
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of VTX3232 (10 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with One or More Serious Adverse Event(s) at Day 24 and Number of Participants with One or More Treatment-Emergent Adverse Event(s) at Day 24. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
VTX3232
Beyond the preview
Go deeper on NCT07867340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07867340.